MedTrace Logo

A Clinical Study of JS005 in Patients With Ankylosing Spondylitis

NCT06250062 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 261

Last updated 2024-02-08

No results posted yet for this study

Summary

This is a multicentre, randomized, double-blind, parallel, placebo-controlled Phase II clinical study of 261 adults with active ankylosing spondylitis to evaluate the efficacy and safety of JS005 in the treatment of active ankylosing spondylitis.

Conditions

Interventions

DRUG

Recombinant humanized IL-17A Monoclonal Antibody（JS005）

Injection

DRUG

Placebo（JS005）

Injection

Sponsors & Collaborators

  • Sponsor GmbH

    collaborator OTHER

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Principal Investigators

  • Huji Xu, PhD · Shanghai Changzheng Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-12
Primary Completion
2025-02-26
Completion
2025-10-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06250062 on ClinicalTrials.gov